Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

Autor:	André Fedier, Nadia Maggi, Alessandra Tozzi, Muriel Disler, Ricardo Coelho, Francis Jacob, Viola Heinzelmann‑schwarz
Rok vydání:	2021
Předmět:	Ovarian Neoplasms Cancer Research Paclitaxel Platinum Compounds Poly(ADP-ribose) Polymerase Inhibitors Piperazines Oncology Doxorubicin Drug Resistance Neoplasm Cell Line Tumor Humans Phthalazines Female Antineoplastic Agents Alkylating
Zdroj:	International journal of oncology. 61(1)
ISSN:	1791-2423
Popis:	Poly (ADP‑ribose) polymerase (PARP)‑inhibitors (PARPi) such as olaparib and niraparib are currently used as a treatment option for
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c38bbdcf2993364795ac2eee5adc53 https://pubmed.ncbi.nlm.nih.gov/35642662 Zobrazit plný text záznamu